on 09 Apr 2024
Last Applicant/ Owned by
SUITE 6990
WOBURN
MA
01801
Serial Number
90217689 filed on 28th Sep 2020
Registration Number
7355827 registered on 09th Apr 2024
Correspondent Address
Ian W. Gillies
Filing Basis
1. intent to use
2. use application currently
Disclaimer
NO DATA
Providing medical and scientific research information in the fields of pharmaceuticals, biochemistry, biotechnology, and clinical trials; drug discovery services; pharmaceutical research; research and development of new probiotic or microbe-targeted phamaceutical products; research in the fields of biochemistry, biotechnology, and conducting clinical trials for others Providing medical informatio Read More
Providing medical information in the fields of diagnostic, prophylactic, and therapeutic properties of probiotic or microbe-targeted pharmaceuticals
24th Oct 2021
24th Oct 2021
Providing medical and scientific research information in the fields of pharmaceuticals, biochemistry, biotechnology, and clinical trials; drug discovery services; pharmaceutical research; research and development of new probiotic or microbe-targeted phamaceutical products; research in the fields of biochemistry, biotechnology, and conducting clinical trials for others
24th Oct 2021
24th Oct 2021
Probiotic or microbe-targeted pharmaceutical preparations and substances for the treatment, prevention, and detection of central nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases, and any disease or disorder associated with intestinal permeability, or leaky gut, and amyloids; chemical, biochemical and microbial products, namely, one or more of small molecules, proteins, antibodies, nucleic acids, probiotic bacteria, probiotic bacterial cultures, and microbes being pharmaceutical preparations and substances for the treatment, prevention, and detection of central nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases, and any disease or disorder associated with intestinal permeability, or leaky gut, and amyloids
20th Dec 2021
20th Dec 2021
Chemicals, biochemicals, cells, and microbes for use in the manufacture of probiotic or microbe-targeted pharmaceutical preparations, for in vitro and in vivo scientific or research use, and for use in industry and science; chemical, biochemical and microbial products, namely, one or more of small molecules, proteins, antibodies, nucleic acids, probiotic bacteria, probiotic bacterial cultures, and microbes for the manufacture of probiotic or microbe-targeted pharmaceutical preparations for the treatment, prevention, and detection of central nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases, and any disease or disorder associated with intestinal permeability, or leaky gut, and amyloids
01st Oct 2022
01st Oct 2022
No 90217689
No Service Mark
No
No
No
No
No
No
No
No
No
26.01.02 -
Plain single line circles
26.01.21 -
Circles that are totally or partially shaded
26.01.31 -
Five or more circles
26.17.01 -
Straight line(s), band(s) or bar(s)
26.17.04 -
Vertical line(s), band(s) or bar(s)
26.17.05 -
Horizontal line(s), band(s) or bar(s)
26.17.06 -
Diagonal line(s), band(s) or bar(s)
Status Date | Action Taken |
---|---|
09th Apr 2024 | REGISTERED-PRINCIPAL REGISTER |
07th Mar 2024 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
06th Mar 2024 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
26th Feb 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
26th Feb 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
26th Feb 2024 | ASSIGNED TO LIE |
04th Oct 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
18th Jul 2023 | SOU TEAS EXTENSION RECEIVED |
21st Jun 2023 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
21st Jun 2023 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |